Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Expected to Rise, Citigroup Analyst Says

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its target price boosted by stock analysts at Citigroup from $50.00 to $60.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price target suggests a potential upside of 14.04% from the company’s previous close.

KNSA has been the subject of several other research reports. Wedbush increased their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a research note on Wednesday. Jefferies Financial Group increased their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday, April 21st. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Canaccord Genuity Group initiated coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They set a “buy” rating and a $62.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.86.

Kiniksa Pharmaceuticals International Stock Down 2.3%

KNSA stock traded down $1.24 during mid-day trading on Wednesday, hitting $52.62. 902,429 shares of the company were exchanged, compared to its average volume of 700,683. The firm has a market capitalization of $4.03 billion, a P/E ratio of 70.99 and a beta of 0.06. The business has a fifty day simple moving average of $46.11 and a 200-day simple moving average of $42.97. Kiniksa Pharmaceuticals International has a 12-month low of $24.85 and a 12-month high of $54.31.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.09. The company had revenue of $214.27 million during the quarter, compared to analyst estimates of $207.12 million. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. Kiniksa Pharmaceuticals International’s revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.11 earnings per share. Research analysts predict that Kiniksa Pharmaceuticals International will post 1.09 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, COO Ross Moat sold 1,703 shares of the stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $46.69, for a total transaction of $79,513.07. Following the sale, the chief operating officer owned 12,029 shares of the company’s stock, valued at approximately $561,634.01. This represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 7,278 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $50.01, for a total transaction of $363,972.78. Following the sale, the chief executive officer directly owned 7,278 shares in the company, valued at $363,972.78. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 61,479 shares of company stock valued at $2,832,812. Corporate insiders own 53.48% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Several hedge funds have recently added to or reduced their stakes in the company. Rubric Capital Management LP raised its holdings in Kiniksa Pharmaceuticals International by 2.3% in the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after acquiring an additional 90,194 shares in the last quarter. Vanguard Group Inc. raised its holdings in Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after acquiring an additional 49,802 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Kiniksa Pharmaceuticals International by 45.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after acquiring an additional 332,846 shares in the last quarter. Qube Research & Technologies Ltd raised its holdings in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after acquiring an additional 653,236 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after acquiring an additional 67,452 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Key Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 beat and raised 2026 revenue guidance — Kiniksa reported $0.27 EPS on $214.3M revenue (EPS and revenue above consensus), revenue +55.5% YoY, and raised 2026 expected net product revenue to $930–$945M. These results and guidance are the primary positive fundamental drivers. GlobeNewswire: Q1 Results
• Positive Sentiment: Analyst upgrades/price-target raises — Jefferies raised its target to $71 (buy, ~32.7% upside), Wells Fargo raised to $57 (overweight, ~6.5% upside), and Wedbush raised to $59 (outperform, ~10.3% upside). Multiple brokerages upping targets signals increased analyst conviction following the quarter. Benzinga: Analyst Notes TickerReport: Jefferies
• Positive Sentiment: Upcoming clinical catalyst — Kiniksa expects Phase 2 data for KPL‑387 in recurrent pericarditis in 2H 2026 and plans to start a Phase 3 pivotal trial by year‑end. Positive clinical readouts and a path to Phase 3 are meaningful potential upside drivers for a specialty pharma name. GlobeNewswire: Pipeline Update
• Positive Sentiment: Strong balance sheet — Q1 cash balance rose to $468.1M, supporting development programs and commercialization. This reduces financing risk as the company advances trials and scales ARCALYST revenue. GlobeNewswire: Cash Position
• Neutral Sentiment: Earnings materials and transcripts available — Full Q1 slide deck, press release, and the earnings call/transcript provide detail for modeling revenue cadence and margin assumptions; investors should review for guidance context and product trends. Slide Deck Seeking Alpha: Presentation Seeking Alpha: Call Transcript
• Neutral Sentiment: Media coverage of results — Coverage from Zacks, MarketBeat and others highlights the beat and guidance; useful for sentiment but not new fundamentals. Zacks: Earnings Coverage MarketBeat: Call Recording

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.